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e-mail address: hkatan@kkesh.med.sa (H.M. Alkatan).Hind M. Alkatan, MD ⇑; Ahmad Alaraj, MD; Albarah El-khani, MSc; Osama Al-Sheikh, MDAbstractPurpose: To study the pattern of ocular adnexal lymphoproliferative disorders (OALD) in an ophthalmic referral center in Saudi
Arabia and to review their, histopathological characteristics with clinical correlation.
Methods: Retrospective chart review of 40 cases of patients who underwent incisional biopsy with the suspected diagnosis of per-
iocular and/or adnexal lymphoid lesions over the period: 2000–2012 at the King Khaled Eye Specialist Hospital (KKESH), Riyadh,
Saudi Arabia. The routine histopathologic slides are reviewed by a single pathologist to identify cases of Benign Reactive Lym-
phoid Hyperplasia (RLH), Atypical Lymphoid Hyperplasia and probable lymphoma. The identification of the specific types of lym-
phoma is performed at a tertiary general hospital: King Faisal Specialist Hospital and Research Centre (KFSH&RC).
Results: Forty patients are included with an age range of 11–91 years and a median of 36 years. The males constitute 70% and
females 30% of the cases. The right eye and/or orbit are involved in 48%. The left eye is involved in 45% while a bilateral disease
is found in 7.5%. The median duration of symptoms is 5 months. The site distribution is conjunctiva (42.5%), orbit (25%), lacrimal
gland (12.5%), eyelid (10%), lacrimal sac (7.5%) and caruncle (2.5%). One case is excluded after histopathologic diagnosis of malig-
nant melanoma. Diagnosis in the remaining 39 cases includes: RLH in 14 cases (35%), atypical lymphoid hyperplasia in three cases
(9%), and lymphoma in 22 cases (56%). Classification of the lymphoma group is: extranodal marginal zone lymphoma (EMZL) in 9/22
cases (41%), diffuse large B cell lymphoma (DLBCL) in 4/22 cases (18%), Castelman’s disease in 3/22 cases (14%), Burkitt’s lymphoma
in 2/22 cases (9%), follicular lymphoma and T cell-rich B cell lymphoma: one case each (4.5%).Two cases remain unclassified.
Conclusion: We have a wide age range which is comparable to other studies. Our results show male predominance and the com-
monest site of involvement is conjunctival, however if RLH cases are excluded, the commonest site for lymphoma is orbit/lacrimal
gland in 45% followed by conjunctival in 23%. The commonest type of lymphoma is: EMZL in 41% followed by DLBCL in 18% then
other types of lymphoma including follicular lymphoma.
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Lymphoproliferative disease of the ocular adnexa
(conjunctiva, eyelids and orbit) is relatively uncommon.
Ocular lymphoma constitutes less than 1% of all non-Hodgkinlymphomas (NHLs) and 5–15% of all extranodal cases. Most
of these are primary tumors and are usually NHLs of B-cell type.
Ithasbeenrecognizedthatmostocularadnexal lymphomasare
lowgrade,extranodal,marginal zone (EMZL)B-cell lymphomas
of the mucosa-associated lymphoid tissue (MALT) type.1e:
al.com
11462,
Table 2. Final diagnosis of the 22 confirmed lymphoma cases.
Lymphoma type No. %
Extranodal marginal zone 9 41
DLBCL 4 18
Castelman’s 3 14
Burkitt’s 2 9
Unclassified 2 9
228 H.M. Alkatan et al.Lymphoproliferative lesions of the ocular adnexa may
present with symptoms of conjunctival salmon patches, pto-
sis from eyelid involvement or the insidious and painless
development of proptosis and/or diplopia due to an orbital
mass. Clinical and radiological features do not allow distinc-
tion of benign hyperplasias from malignant lymphoma, and
tissue is ultimately required for histological diagnosis.1,2Follicular 1 4.5
T cell-rich B cell 1 4.5Methods
Retrospective review of the medical records of 40 cases of
patients who underwent incisional biopsy with the suspected
diagnosis of periocular and/or adnexal lymphoid tumors over
the period of 2000–2012 at KKESH is performed. Special data
collection sheet is designed to include demographic data,
clinical information (including site of disease/relevant medical
history/ocular symptoms) and histopathological diagnosis.
The routine histopathologic slides are reviewed by a single
pathologist at our institution; however the completion of the
panel of all immunohistochemical (IHC) stainings designed
for suspected lymphoma cases and the final histopathologic
diagnosis are performed at KFSH&RC where such patients
have been usually referred for staging and further
management.
This work has been performed with the approval of the Re-
search Council and Human Ethics Committee at the
institution.Results
A total number of 40 patients are included with an age
range of 11–91 years and a median of 36 years. The males
constitute 70% and females 30% of the cases. The right eye
and/or orbit is involved in 48%. The left eye is involved in
45% while a bilateral disease is found in 7.5% of the cases.
The clinical presentation is summarized in Table 1. The
median duration of symptoms is 5 months. One case only
has evidence of systemic lymphoma.
The site distribution was conjunctiva (42.5%), orbit (25%),
lacrimal gland (12.5%), eyelid (10%), lacrimal sac (7.5%) and
caruncle (2.5%).
Following histopathologic identification of the 40 cases,
one case is excluded because of the final tissue diagnosis
of malignant melanoma. The distribution of the remaining
39 cases according to the tissue diagnosis is: RLH in 14 cases
(35%), atypical lymphoid hyperplasia in three cases (9%), and
lymphoma in 22 cases (56%).
The classification of cases in the lymphoma group is sum-
marized in Table 2. The commonest being EMZL (Fig. 1a and
b) in 9/22 cases (41%), Diffuse Large B cell lymphoma
(DLBCL) in 4/22 cases (18%) with a clinical example shown
in (Fig. 2a–c), Castleman’s disease (Fig. 3) in 3/22 casesTable 1. The main presenting symptoms of 40 cases.
Symptom Frequency %
Dryness 2.5
Globe displacement 5
Reduced vision 10
PtosisP 2 mm 12.5
Eyelid swelling and/or edema 17.5
Proptosis 20
Conjunctival mass 42.5(14%), Burkitt’s lymphoma (Fig. 4) in 2/22 cases (9%), follicular
lymphoma (Fig. 5a and b) and T cell-rich B cell lymphoma:
one case each (4.5%). Two cases remain unclassified.
Discussion
Ocular adnexal lymphoma (OAL) is considered primary if it
involves the ocular adnexa alone and secondary if it is accom-
panied by a lymphoma of identical type at another site. The
extent of OAL is defined as solitary if it involves one or both
orbits, extension if it involves contiguous sites such as the si-
nuses, and systemic if remote sites are involved.1–3
Previous studies have demonstrated that with sufficiently
long follow up, between one-third and one-half of the pa-
tients with OALD develop systemic lymphoma. In our case
series, one patient only has shown evidence of systemic lym-
phoma. .It has been recognized that the majority of the pri-
mary ocular adnexal lymphomas are low-grade tumors, with
features of extranodal marginal zone lymphoma (EMZL).
These tumors are generally localized at presentation.1–4,7
The frequency of the involvement of periocular sites has
been reported as follows: conjunctiva, 20–33%; orbit, 46–
74%; and eyelid, 5–20%. These numbers are somewhat vari-
able and may not reflect as clear a distinction as implied, be-
cause separation between these immediately proximate
structures can be difficult to make, and few studies describe
combinations of sites of involvement. Estimates of multisite
involvement range from 10% to 20%. Bilaterality is reported
in 10–20% of cases.1,2,7 In our cases -with exclusion of RLH-,
the commonest site for lymphoma is orbit/lacrimal gland in
45% followed by conjunctival in 23%. Bilaterality was similarly
found in 7.5%.
Classification schemes of lymphomas have evolved with
time from those based on morphology alone such as the
working formulation to the most recent proposed World
Health Organization Classification and its precursor, Revised
European American Lymphoma Classification (REAL), which
incorporate clinical features and ancillary laboratory investi-
gations such as immunophenotyping and genotyping in addi-
tion to the histopathological findings. Recent reports of
ocular adnexal lymphomas demonstrated that this classifica-
tion scheme was useful in prediction of the stage of disease
at diagnosis, persistence of disease at the final follow up
and lymphoma-related death.7
Clinical and imaging data cannot be used to make the
diagnosis of OAL with certainty. Diagnosis is made based
on a combination of histopathologic, immunophenotypic,
and molecular genetic information. Diagnostically, three
questions are asked: (1) Is the lesion malignant (OAL), transi-
tional (atypical RLH), or benign (RLH)? (2) What specific type
of OAL is present? (3) Can specific prognostic features be
identified?1,3,7
Figure 2. (A) and (B): The clinical appearance of right orbital swelling in a
patient with DLBCL. The histopathologic appearance of the large
lymphocytes infiltrating the orbital fat is shown in (2C) (Hematoxylin &
eosin original magnification x100).
Figure 3. The histologic appearance of the lymphoid cells in Castleman’s
disease affecting a lacrimal gland (Hematoxylin & eosin original magni-
fication x200).
Figure 4. The classic ‘‘starry sky ‘‘ histologic appearance in a case of
Burkitt’s lymphoma affecting an 11 year old girl (Hematoxylin & eosin
original magnification x200).
Figure 1. (A) and (B): The low power appearance of the EMZL Lymphoma (Hematoxylin & eosin original magnification x50) with higher magnification
showing diffuse sheets of mature lymphocytes in 1B (Hematoxylin & eosin original magnification x100).
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of the degree of malignancy. Nevertheless, because theWHO classification is dependent on immunophenotyping
and molecular genetic data, lymphoproliferative lesions
should undergo immunophenotypic analysis (IPA) for B-cell
and T-cell markers, heavy and light chain restriction, CD5,
CD10, CD23, cyclin D1, and bcl-2. When possible based on
the amount of available tissue, flow cytometry should be per-
formed because of its quantitative nature.1–3,7
Immunohistochemical (IHC) analysis can answer several
general questions. The histologically similar mantle cell and
marginal cell tumors can usually be distinguished owing to
the differential expression of CD5.1–7 Molecular genetic anal-
ysis for gene rearrangements of the IgG heavy chain can
identify clonality at a much more sensitive level but can pro-
vide false positive data (especially in PCR-amplified studies)
based on sampling problems.1–3
In our case series, the final classification of our 22 sus-
pected lymphoma specimens were dealt with by professional
pathologist in the field using the necessary IHC characteris-
tics and gene rearrangement at KFSH&RC. The commonest
type of lymphoma is: EMZL in 41% followed by DLBCL in
18% then other types of lymphoma including follicular
lymphoma.
Ocular adnexal lymphomas are mainly B-cell tumors devel-
oping in older adults, predominantly among women. In our
study we had a wide range of ages at presentation with male
predominance in 70%.
Figure 5. (A) and (B): The low power appearance of a follicular Lymphoma (Hematoxylin & eosin original magnification x25) with higher magnification
showing proliferating lymphocytes in (5B) (Hematoxylin & eosin original magnification x100).
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have primary orbital disease. White et al. in a review of 42
cases, had one case only out of 16 MALT lymphoma as sec-
ondary.4 In our study we had a single known case of lym-
phoma with secondary orbital involvement.
With regard to the site, some authors suggest dominance
of RLH in the conjunctiva compared to the orbit, while others
state the opposite.5,6 Coupland et al. diagnosed RLH in 10%
of all patients with ocular adnexal lymphoid proliferation,
which represents 16% of orbital cases but 10% of the con-
junctival lesions.2 In our study we had RLH in 36% of all cases,
which constituted 12/17 of our conjunctival lesions in partic-
ular (71%). The distribution of site was a higher proportion
of conjunctival lesions in 42.5%, possibly because of easy
accessibility, Orbit and/or lacrimal gland in 37.5%, Eyelid
involvement was in 10%, Lacrimal sac in 7.5% and the least
common was in the caruncle 2.5%.
It has been suggested that there are no characteristic
symptoms for orbital malignant lymphoma.8 In White et al.
review, the commonest presenting symptoms were mass in
48% or swelling in 45%, followed by diplopia, ptosis then
proptosis.4 Our commonest presenting symptom was also a
mass or swelling in 42.5% and 17.5% of the cases, followed
by proptosis, ptosis and vision disturbance.
Management of OAL is optimally an integrated multidisci-
plinary endeavor requiring a comprehensive staging evalua-
tion. A thorough physical examination by a physician
familiar with lymphoma is optimal. The use of ancillary stag-
ing studies has evolved with the development of new imag-
ing modalities. Imaging and fine-needle biopsy have
replaced laparotomy, although some question the ability of
fine-needle aspiration biopsy to obtain diagnostically repre-
sentative specimens.1,3,7
The selection of treatment for OAL is dependent on the
specific tumor type and its staging. Controversy exists as to
whether OAL is curable. Those who believe so pursue more
aggressive but potentially toxic therapies, whereas those
who believe it is not curable may treat indolent disease onlyas it becomes symptomatic or transforms to high-grade
lymphoma. Other clinicians will treat the patient based on
an attempt to prevent transformation to a high-grade lym-
phoma. In some cases, observation without intervention is
selected.1–7
The patients in our series are all managed at other general
health care facilities and the discussion of their treatment
outcome is beyond the scope of this paper.
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